In the healthy colon, the epithelium, immune cells and commensal microbes collaboratively maintain a stable equilibrium that both preserves intestinal health and protects the gut from potential threats.
BARRIER BREAKDOWN
In people with ulcerative colitis, factors such as a genetic predisposition, environmental triggers and infection set into motion a cycle of uncontrolled in ammation that wreaks havoc on the intestinal wall.
ANATOMY OF A BARRIER
The events that underlie the onset of ulcerative colitis are not well understood. Disruption of the intestinal wall is thought to enable bacteria in the lumen that are normally well tolerated (or even bene cial to health) to trigger a poorly controlled immune response that causes chronic in ammation and tissue damage.
Epithelium
Epithelial cells are coupled together by tight junctions, which form a strict seal that prevents microbes in the lumen from triggering an immune response.
Mucous membrane
Commensal microbes reside in the mucous membrane that lines the epithelium. They help epithelial cells to both maintain a tight seal and fend o disease-causing bacteria.
Tight junctions are disrupted, enabling microbes to cross from the lumen into the lamina propria.
Macrophages and dendritic cells engulf microbes and send out in ammatory signals that heighten the immune response.
The resulting activation of T cells in icts further in ammatory damage on the epithelium and attracts other immune cells to the site.
Dendritic cell
Dendritic cells monitor the lumen for pathogenic species using long projections that span the epithelium. When a threat is detected, they activate T cells in the lamina propria, stimulating a broader immune response.
Regulatory T cell
Commensal microbes help to maintain a healthy immune system by producing molecules that regulate the activity of immunosuppressive regulatory T cells. 
A CALL FOR REINFORCEMENTS
Fresh strategies for delivering relief to people with ulcerative colitis who no longer bene t from existing therapies are being explored in clinical trials. A wide variety of work is under way, but four broad approaches seem to hold particular promise.
FIGHTING THE FLAMES
Treatments that promote and maintain remission from ulcerative colitis do not work in all people, and some can cause serious side e ects.
Corticosteroids
Anti-in ammatory drugs act on immune cells and the epithelium, and are used to treat severe ulcerative colitis. However, they are associated with side e ects and dependency.
Immunosuppressants
Drugs such as azathioprine deliver sustained relief by limiting T-cell numbers, but this can leave recipients vulnerable to infection and other side e ects.
Aminosalicylates
Mesalazine (5-aminosalicylic acid) can quell the production of in ammatory signals, but the drug is e ective mainly in people with mild to moderate disease. Drugs that bind to the sphingosine-1-phosphate receptor on T cells, such as etrasimod, aim to halt in ammation by interfering with T-cell migration.
Biological drugs
Etrolizumab also stops T cells that are already in the lamina propria from attaching to the epithelium. The antibody drug is currently in phase III trials.
Antibody-based drug UTTR1147A activates the IL-22 receptor on epithelial cells to set this healing in motion.
It is now being tested in a phase II trial.
TRAFFIC CONTROL
Limiting the ingress of immune cells into the lamina propria could control localized in ammation without the need for broad immunosuppression.
Etrolizumab prevents T cells from crossing from blood vessels into the lamina propria by blocking a crucial binding protein. 
MENDING FENCES
Drugs that target the cytokine IL-22 might counteract damage in ulcerative colitis by reinforcing the epithelium and halting leakage of immunitytriggering microbes into the lamina propria.
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BENEVOLENT BUGS
Supplementing existing microbes in the colon might help to quell in ammation and restore normal intestinal function. 
